MS Therapy Centre

Information About our News Feeds

The News Feeds displayed on this page are collected and updated from reputable 3rd Party Resources and Publications both National and International. The Wolverhampton MS Therapy Centre takes care in only including those resources it feels may benefit its Clients and Carers.

Occasionally some News Feeds are not made available for us to display and an error message may appear above, this simply means that a particular news article about MS is not available and does not affect the integrity of this site.

The Wolverhampton MS Therapy Centre cannot accept any legal responsibility for the accuracy or relevance of any information or any consequences that may arise from any actions taken from any information made available from the supplied News Feeds.

All information that is collected and displayed is offered in good faith.

Latest Multiple Sclerosis News

Stopping Tysabri Early Tied to Active PPMS, Smoking and Depression in Patients, Study Finds
Multiple Sclerosis News Today Feb 26, 2020 | 07:15 am
The likelihood of discontinuing treatment with Tysabri (natalizumab) is higher among patients with progressive relapsing multiple sclerosis, and those who smoke and are depressed, a study reported. Progressive relapsing MS (PRMS) is now largely considered a subset of primary progressive[…]
Read more...
Potential Therapy, Anavex 2-73, Shows Ability to Protect Neurons and Promote Myelin in Early Tests
Multiple Sclerosis News Today Feb 26, 2020 | 07:00 am
Anavex Life Sciences‘ investigational therapy Anavex 2-73 (blarcamesine) showed an ability to protect, repair, and induce the formation of oligodendrocytes — the cells that produce the protective myelin layer around neurons — in early cell testing, researchers reported. These findings,[…]
Read more...
Diroximel Fumarate Is Approved for Relapsing Forms of MS, Clinically Isolated Syndrome
Multiple sclerosis on Neurology Times Nov 15, 2019 | 13:01 pm
The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.
Read more...
Tecfidera Generic Granted Tentative FDA Approval as Patent Assault Continues
Multiple sclerosis on Neurology Times Oct 16, 2019 | 12:36 pm
The latest generic entry comes on the heels of a new report from ICER, which published a list of prescription drugs that had substantial price increases in 2017 and 2018 without what they consider to be new supporting evidence.
Read more...
Video Campaigns
Society for Multiple Sclerosis Patients in Pakistan Jun 13, 2018 | 02:08 am
Apart from the #LetsBeatMS campaign, the Radio Campaign, and Media Coverage, the Society for Multiple Sclerosis Patients in Pakistan also started a Video campaign on Social Media Platforms. The first video was a mini documentary on my Life with MS,[…]
Read more...
Media Coverage
Society for Multiple Sclerosis Patients in Pakistan Jun 12, 2018 | 11:22 am
The Society for Multiple Sclerosis Patients in Pakistan gave several interviews to News channels around World MS Day 2018 to help raise awareness about Multiple Sclerosis. The interviews were broadcasted on Royal News. Another interview was given to Muhammad Rizwan[…]
Read more...